Cingulate therapeutics headquarters
WebMay 8, 2014 · Moelis & Company acted as financial advisor to Lundbeck, while Cravath, Swaine & Moore acted as legal advisers. For Chelsea Therapeutics, Deutsche Bank Securities and Torreya Capital acted as financial advisors, while Morgan, Lewis & Bockius acted as legal advisers. Image: Lundbeck headquarters in Valby, Denmark. Photo: … WebCingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical...
Cingulate therapeutics headquarters
Did you know?
WebJun 15, 2024 · KANSAS CITY, Kan., June 15, 2024 /PRNewswire/ -- Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on... WebAGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of August 30, 2024 by and among Cingulate Therapeutics LLC, a Delaware limited liability company (“CTx”), Cingulate Inc., a Delaware corporation and wholly-owned subsidiary of CTx (“Parent”), and Cingulate Pharma LLC, a Delaware limited liability company and a wholly owned ...
WebCingulate is headquartered in Kansas City. For more information visit Cingulate.com. Forward-Looking Statements This press release contains certain forward-looking statements, including those relating to the use of proceeds and other statements that are predictive in nature. WebCingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate Therapeutics is registered under the ticker NASDAQ:CING . Their stock opened with $6.00 in its Dec 8, 2024 IPO.
WebMr. Peter Werth serves as Board Member at Cingulate Therapeutics. He is the Founder and also serves as Chief Executive Officer at Werth Ventures. He serves as Board Member at Alopexx Enterprises. He is the Owner & serves as the Chief Executive Officer & President at Chemwerth. He also served as a board member at InnoPharma. WebCingulate's headquarters are located at 1901 W 47th Pl, Kansas City, Kansas, 66205, United States What is Cingulate's phone number? Cingulate's phone number is (913) …
WebJul 11, 2024 · 11 Jul 2024 Cingulate CEO: $7.5M fundraising round will help drive pharma growth in KC. A former Marion Laboratories employee, Shane Schaffer’s goal from the …
WebFind the latest Cingulate Inc. (CING) stock quote, history, news and other vital information to help you with your stock trading and investing. jnj whisper numberWebApr 3, 2024 · Cingulate Therapeutics doesn't have any recent trademark applications, indicating Cingulate Therapeutics is focusing on its existing business rather than … jnj wound closureWebCingulate Therapeutics 9 years 11 months Chief Operating Officer Oct 2024 - Present5 years 7 months Kansas City, KS Founding member of … institute of chemical biologyWebCingulate Therapeutics is a biopharmaceutical company developing products for the treatment of central nervous system and neurobiological disorders. jnk abbreviationWebView Arthur Straughn's business profile as Co-founder Board of Directors at Cingulate Therapeutics. Find Arthur's email address, mobile number, work history, and more. Product About Create Free Account. Wrong ... Arthur Straughn's HQ phone number is +1 913-942-2300. Who are Arthur Straughn's colleagues? Arthur Straughn's colleagues are Lou Horn ... jnk aestheticsWebJun 15, 2024 · Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products … institute of chartering and ship brokeringWebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member … jnj warehouse locations